2012 has been a big year for the Biotech industry, particularly for companies in the early stages of venture funding. Since 2008, a total of 204 Biotech companies have received financing from VC investors, spanning 367 deals. So far this year, activity in later-stage companies has waned a bit, but the total number of deals taking place in the sector so far this year comes to 89—a marked increase from previous years. Early-stage financings have been especially hot in 2012, representing 58 of the 89 total deals, as opposed to last year’s 37. On the investment front, Kleiner Perkins Caufield & Byers is the clear frontrunner, tallying up nine investments over the same the time period, followed by ARCH Venture Partners, Morgenthaler and Novo A/S, all of which have eight.
PitchBook Platform users can click on the chart above or here to customize it.